MedElevator
Войти в исследования Allergy · 2026
Tezepelumab Reverses TSLP-Driven Immunometabolic Rewiring in Human cDC2s Underlying Pathogenic Th2 and Dysfunctional Treg Responses.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martín-Cruz Leticia, de la Rocha-Muñoz Andrés, Peñalver-Fernández Isabel María, Maldonado Ángel, Sirvent Sofía, Palomares Oscar
Аннотация
BACKGROUND: Thymic stromal lymphopoietin (TSLP) is a key epithelial alarmin involved in the initiation and maintenance of type 2 inflammatory airway diseases. Although tezepelumab, the first approved anti-TSLP monoclonal antibody, has shown robust clinical efficacy in asthma and CRSwNP, the molecular mechanisms underlying its mode of action remain incompletely defined.
OBJECTIVE: To determine whether TSLP induces a pathogenic immunometabolic program in human type 2 conventional dendritic cells (cDC2s) and whether tezepelumab can directly reverse this process.
METHODS: Purified human circulating cDC2s from healthy non-atopic donors were stimulated with TSLP in the presence or absence of tezepelumab. cDC2 phenotype, function, metabolism, and T-cell polarization capacity were assessed. Pathogenic Th2 responses, Treg generation, suppressive function, and metabolic fitness were analyzed.
RESULTS: TSLP induced a metabolic rewiring in human cDC2s characterized by increased glycolysis and mitochondrial oxidative phosphorylation. This metabolic hyperactivation was associated with the acquisition of a pro-type 2 phenotype and required for the induction of pathogenic T-cell responses. TSLP-activated cDC2s generated pathogenic Th2 cells and FOXP3+ Tregs with impaired suppressive function and an altered metabolic profile. Tezepelumab effectively reversed TSLP-induced metabolic and functional reprogramming in cDC2s, thereby limiting pathogenic Th2 polarization while restoring the functional and metabolic properties of induced Tregs.
CONCLUSIONS: We identify immunometabolic rewiring as a key mechanism of the TSLP-cDC2 axis and provide mechanistic insight into how tezepelumab reshapes pathogenic adaptive immune responses. These results support upstream epithelial alarmin blockade as a strategy to interfere with early disease-driving immune programs in type 2 inflammatory airway diseases.
OBJECTIVE: To determine whether TSLP induces a pathogenic immunometabolic program in human type 2 conventional dendritic cells (cDC2s) and whether tezepelumab can directly reverse this process.
METHODS: Purified human circulating cDC2s from healthy non-atopic donors were stimulated with TSLP in the presence or absence of tezepelumab. cDC2 phenotype, function, metabolism, and T-cell polarization capacity were assessed. Pathogenic Th2 responses, Treg generation, suppressive function, and metabolic fitness were analyzed.
RESULTS: TSLP induced a metabolic rewiring in human cDC2s characterized by increased glycolysis and mitochondrial oxidative phosphorylation. This metabolic hyperactivation was associated with the acquisition of a pro-type 2 phenotype and required for the induction of pathogenic T-cell responses. TSLP-activated cDC2s generated pathogenic Th2 cells and FOXP3+ Tregs with impaired suppressive function and an altered metabolic profile. Tezepelumab effectively reversed TSLP-induced metabolic and functional reprogramming in cDC2s, thereby limiting pathogenic Th2 polarization while restoring the functional and metabolic properties of induced Tregs.
CONCLUSIONS: We identify immunometabolic rewiring as a key mechanism of the TSLP-cDC2 axis and provide mechanistic insight into how tezepelumab reshapes pathogenic adaptive immune responses. These results support upstream epithelial alarmin blockade as a strategy to interfere with early disease-driving immune programs in type 2 inflammatory airway diseases.